$ILMN Illumina said Thursday it expects second-quarter revenue to be roughly flat year-over-year at $835 million, which is short of the $890 million expected, de Bruin said in a Friday note. The miss can be attributed to three areas, the analyst said: A sizable sequencing systems and consumables purchase that will close later in 2019.Softness in the direct-to-consumer genomic market.Low to mid-throughput NGS systems and consumables.